It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:

Gilead Sciences: "But [the hepatitis C cure is] a cure, sir. That's the problem. It's a cure. And the people who do really well in that business do maintenance therapeutics and they can keep people alive for a long time. This is a cure. It's one and done, which is fabulous, but it's not great for the stock. It yields 3 and a quarter [percent]. If they were just to go buy Incyte… Listen to me: Gilead, go buy Incyte this weekend and I'll go bullish on you. Otherwise, don't buy."